Subject Retention in Prehospital Stroke Research Using a Telephone-Based Physician-Investigator Driven Enrollment Method.


Journal

Cerebrovascular diseases extra
ISSN: 1664-5456
Titre abrégé: Cerebrovasc Dis Extra
Pays: Switzerland
ID NLM: 101577885

Informations de publication

Date de publication:
2019
Historique:
received: 11 04 2019
accepted: 09 05 2019
pubmed: 26 7 2019
medline: 12 2 2020
entrez: 26 7 2019
Statut: ppublish

Résumé

Subject retention into clinical trials is vital, and prehospital enrollment may be associated with higher rates of subject withdrawal than more traditional methods of enrollment. We describe rates of subject retention in a prehospital trial of acute stroke therapy. All subjects were enrolled into the NIH Field Administration of Stroke Therapy-Magnesium (FAST-MAG) phase 3 clinical trial. Paramedics screened eligible subjects and contacted the physician-investigator using a dedicated in-ambulance cellular phone. Physician-investigators obtained explicit informed consent from the subject or on-scene legally authorized representative (LAR) who reviewed and signed a consent form. Exception from informed consent (EFIC) was utilized in later stages of the study. There were 1,700 subjects enrolled; 1,017 provided consent (60%), 662 were enrolled via LAR (39%), and 21 were enrolled via EFIC (1%). Of the 1,700 patients, 1,413 (83%) completed the 90-day visit, 265 (16%) died prior to the 90-day visit, and 22 (1.3%) withdrew from the study before completion. There were no differences in rates of withdrawal by method of study enrolment, i.e., self-consent (n = 14), 1.4%; LAR (n = 8), 1.2%; EFIC (n = 0) 0%. There was a high rate of retention when subjects were enrolled into prehospital stroke research using a phone-based method to obtain explicit consent.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Subject retention into clinical trials is vital, and prehospital enrollment may be associated with higher rates of subject withdrawal than more traditional methods of enrollment. We describe rates of subject retention in a prehospital trial of acute stroke therapy.
METHODS METHODS
All subjects were enrolled into the NIH Field Administration of Stroke Therapy-Magnesium (FAST-MAG) phase 3 clinical trial. Paramedics screened eligible subjects and contacted the physician-investigator using a dedicated in-ambulance cellular phone. Physician-investigators obtained explicit informed consent from the subject or on-scene legally authorized representative (LAR) who reviewed and signed a consent form. Exception from informed consent (EFIC) was utilized in later stages of the study.
RESULTS RESULTS
There were 1,700 subjects enrolled; 1,017 provided consent (60%), 662 were enrolled via LAR (39%), and 21 were enrolled via EFIC (1%). Of the 1,700 patients, 1,413 (83%) completed the 90-day visit, 265 (16%) died prior to the 90-day visit, and 22 (1.3%) withdrew from the study before completion. There were no differences in rates of withdrawal by method of study enrolment, i.e., self-consent (n = 14), 1.4%; LAR (n = 8), 1.2%; EFIC (n = 0) 0%.
CONCLUSION CONCLUSIONS
There was a high rate of retention when subjects were enrolled into prehospital stroke research using a phone-based method to obtain explicit consent.

Identifiants

pubmed: 31344699
pii: 000500851
doi: 10.1159/000500851
pmc: PMC6738216
doi:

Substances chimiques

Neuroprotective Agents 0
Magnesium Sulfate 7487-88-9

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

72-76

Informations de copyright

© 2019 The Author(s) Published by S. Karger AG, Basel.

Références

J Community Health. 1996 Oct;21(5):315-27
pubmed: 8894959
Cerebrovasc Dis. 2009;28(6):539-44
pubmed: 19844092
J Stroke Cerebrovasc Dis. 2016 Jun;25(6):1371-80
pubmed: 27009610
Int J Stroke. 2014 Feb;9(2):220-5
pubmed: 24444117
Contemp Clin Trials. 2016 Jul;49:65-9
pubmed: 27327780
Prehosp Emerg Care. 2006 Apr-Jun;10(2):182-5
pubmed: 16531374
N Engl J Med. 2015 Feb 5;372(6):528-36
pubmed: 25651247
Int J Stroke. 2014 Feb;9(2):215-9
pubmed: 24444116
Acad Emerg Med. 2010 Oct;17(10):1104-12
pubmed: 21040112
Farm Hosp. 2016 May 01;40(3):209-18
pubmed: 27145389

Auteurs

Bryant J Rosell (BJ)

Keck School of Medicine, Department of Neurology, University of Southern California, Los Angeles, California, USA.

Kristina Shkirkova (K)

Keck School of Medicine, Department of Neurology, University of Southern California, Los Angeles, California, USA, kristina.shkirkova@usc.edu.

Jeffrey L Saver (JL)

Stroke Center, Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA.

David S Liebeskind (DS)

Stroke Center, Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA.
Neuroimaging Research Core, Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA.

Sidney Starkman (S)

Stroke Center, Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA.

May Kim-Tenser (M)

Keck School of Medicine, Department of Neurology, University of Southern California, Los Angeles, California, USA.
Roxanna Todd Hodges Comprehensive Stroke Clinic, Department of Neurology, University of Southern California, Los Angeles, California, USA.

Marc Eckstein (M)

Keck School of Medicine, Department of Neurology, University of Southern California, Los Angeles, California, USA.

Latisha Sharma (L)

Stroke Center, Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA.

Robin Conwit (R)

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Massachusetts, USA.

Scott Hamilton (S)

Department of Neurology, Stanford University, Palo Alto, California, USA.

Nerses Sanossian (N)

Keck School of Medicine, Department of Neurology, University of Southern California, Los Angeles, California, USA.
Roxanna Todd Hodges Comprehensive Stroke Clinic, Department of Neurology, University of Southern California, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH